NeuroDiagnostics (“NDx”) has the only minimally invasive highly accurate test, DISCERN™, for Alzheimer’s Disease. Multidisciplinary teams at the NIH and the Rockefeller Neurosciences Institute, led by Dr. Alkon, over the last 30 years led to the development of the three biomarkers. The three biomarkers comprise an AD-Index assay, a Morphometric Imaging assay, and a PKC Epsilon assay. FDA has granted NDx Breakthrough Status. Our diagnostic biomarkers have been confirmed by autopsy validation (NIH “Gold Standard”).
AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves the predictability of study timelines, reduces costs, and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100, and Digital Health 150.
Aiforia is a first-in-class, versatile cloud-based platform that increases the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields. The precise and robust technology, based on deep-learning AI, is intuitive and only requires an internet connection and the user’s own domain knowledge to begin training AI models, which can help solve some of today’s most complex image analysis problems facing researchers, pathologists, radiologists, clinicians and other healthcare professionals.
Established in 2007, Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. Our technology platform, Simoa®, has the potential to change today’s approach to healthcare by giving researchers the ability to closely examine the continuum from health to disease. Simoa® is designed to enable earlier disease detection, better prognoses and enhanced treatment methods. The company is located in Billerica, MA.